Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd. - Common Shares (NQ:CYTO)

0.3001 UNCHANGED
Last Price Updated: 3:55 PM EST, Dec 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altamira Therapeutics Ltd. - Common Shares

< Previous 1 2 3 4 Next >
News headline image
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia
Via ACCESSWIRE
News headline image
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability
Via ACCESSWIRE
News headline image
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Reverse Stock Split
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Participate at RNA Leaders USA Congress
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint... 
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal
HAMILTON, BERMUDA / ACCESSWIRE / July 12, 2022 / Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical... 
From Altamira Therapeutics Ltd.
Via AccessWire
Topics Death
News headline image
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan
Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
HAMILTON, BERMUDA / ACCESSWIRE / June 27, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19
HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo
HAMILTON, BERMUDA / ACCESSWIRE / June 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics Ltd.
Via AccessWire
News headline image
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements
HAMILTON, BERMUDA / ACCESSWIRE / June 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray
HAMILTON, BERMUDA / ACCESSWIRE / June 8, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia
HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray
HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
Company's drug-free nasal spray demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls as well as good tolerability and safety 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Issues Shareholder Letter
Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd.... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
HAMILTON, BERMUDA / ACCESSWIRE / April 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
- Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern. - Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliver -... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant
Study Confirms in vitro Efficacy / Safety of Bentrio(TM) for Delta Variant - Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls... 
From Altamira Therapeutics
Via AccessWire
News headline image
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET
HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it... 
From Altamira Therapeutics
Via AccessWire
Topics Earnings
News headline image
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio
HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.